VARIABILITY IN THE DISPOSITION OF CHLORZOXAZONE

被引:20
作者
DEVRIES, JD
SALPHATI, L
HORIE, S
BECKER, CE
HOENER, BA
机构
[1] UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARM,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,CTR ENVIRONM & OCCUPAT HLTH,SAN FRANCISCO,CA
关键词
CHLORZOXAZONE; CYTOCHROME P450 2E1 PHENOTYPE; HUMAN VARIABILITY; 6-HYDROXYCHLORZOXAZONE; PHARMACOKINETICS;
D O I
10.1002/bdd.2510150706
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chlorzoxazone is 6-hydroxylated by cytochrome P450 2E1 (CYP 2E1), which bioactivates many toxic and carcinogenic molecules. Seventeen volunteers of varying age, ethnicity, and gender received a 250 mg tablet of chlorzoxazone and their blood and urine were sampled frequently for 8 h. V/F = 42 +/- 21 L and CL/F = 412 +/- 120 mL min(-1). Comparison of these values with a study by other investigators using a suspension dosage form suggested that relative F(tablet)similar to 0.7. The fraction excreted in the urine as 6-hydroxychlorzoxazone (f(e,6-OH)) was 0.39 +/- 0.20 and that portion of the total CL accounted for by CYP 2E1-mediated metabolism (CL(6-OH)) was 163 +/- 95 mL min(-1). Thus, while V/F and CL/F varied by factors of less than five, f(e,6-OH) varied 16-fold and CL(6-OH) varied 28-fold. These results suggested that there was considerable inter-individual variability in the metabolism of chlorzoxazone to 6-hydroxychlorzoxazone. This variability will significantly affect the construction of physiologically based pharmacokinetic models that use the 6-hydroxylation of chlorzoxazone as a marker for an individual's CYP 2E1 phenotype.
引用
收藏
页码:587 / 597
页数:11
相关论文
共 10 条
[1]   BOTH CYTOCHROMES P450 2E1 AND 1A1 ARE INVOLVED IN THE METABOLISM OF CHLORZOXAZONE [J].
CARRIERE, V ;
GOASDUFF, T ;
RATANASAVANH, D ;
MOREL, F ;
GAUTIER, JC ;
GUILLOUZO, A ;
BEAUNE, P ;
BERTHOU, F .
CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (06) :852-857
[2]  
CONNEY AH, 1960, J PHARMACOL EXP THER, V128, P340
[3]   PHARMACOKINETICS OF CHLORZOXAZONE IN HUMANS [J].
DESIRAJU, RK ;
RENZI, NL ;
NAYAK, RK ;
NG, KT .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (09) :991-994
[4]   OXIDATION OF TOXIC AND CARCINOGENIC CHEMICALS BY HUMAN CYTOCHROME-P-450 ENZYMES [J].
GUENGERICH, FP ;
SHIMADA, T .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (04) :391-407
[5]   ROLE OF HUMAN CYTOCHROME-P-450-IIE1 IN THE OXIDATION OF MANY LOW-MOLECULAR-WEIGHT CANCER SUSPECTS [J].
GUENGERICH, FP ;
KIM, DH ;
IWASAKI, M .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (02) :168-179
[6]   PREDICTING THE HEPATIC-CLEARANCE OF XENOBIOTICS IN HUMANS FROM IN-VITRO DATA [J].
HOENER, BA .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1994, 15 (04) :295-304
[7]   LIQUID-CHROMATOGRAPHY IN PHARMACEUTICAL ANALYSIS .10. DETERMINATION OF CHLORZOXAZONE AND HYDROXY METABOLITE IN PLASMA [J].
HONIGBERG, IL ;
STEWART, JT ;
COLDREN, JW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (02) :253-255
[8]   SINGLE-DOSE DISULFIRAM INHIBITION OF CHLORZOXAZONE METABOLISM - A CLINICAL PROBE FOR P450-2E1 [J].
KHARASCH, ED ;
THUMMEL, KE ;
MHYRE, J ;
LILLIBRIDGE, JH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :643-650
[9]  
KOOP DR, 1992, FASEB J, V6, P24
[10]   HYDROXYLATION OF CHLORZOXAZONE AS A SPECIFIC PROBE FOR HUMAN LIVER CYTOCHROME-P-450IIE1 [J].
PETER, R ;
BOCKER, R ;
BEAUNE, PH ;
IWASAKI, M ;
GUENGERICH, FP ;
YANG, CS .
CHEMICAL RESEARCH IN TOXICOLOGY, 1990, 3 (06) :566-573